Patents Assigned to TEGO SCIENCE INC
-
Patent number: 11946051Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.Type: GrantFiled: November 21, 2022Date of Patent: April 2, 2024Assignee: Tego Science Inc.Inventors: Saewha Jeon, Ho Yun Chung, Na Ra Oh, Yun Hee Kim, Jikhyon Han, Hyun Ah Moon
-
Publication number: 20230277601Abstract: The present invention relates to human skin-derived fibroblasts having a tendon regeneration effect and a pharmaceutical composition for regenerating and treating a tendon, and the allogeneic skin-derived fibroblasts may have similar cell morphology to tenocytes, have a high expression level of vimentin, which is a fibroblast marker, express a large amount of extracellular matrix proteins, TGF-?, and increase collagen synthesis by acting on an ERK signaling mechanism, thereby effectively regenerating an injured tendon.Type: ApplicationFiled: May 4, 2021Publication date: September 7, 2023Applicant: Tego Science Inc.Inventors: Saewha JEON, Jikhyon HAN, Yun Hee KIM, Ji-Hye LEE
-
Publication number: 20230124032Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.Type: ApplicationFiled: November 21, 2022Publication date: April 20, 2023Applicant: Tego Science Inc.Inventors: Saewha JEON, Ho Yun CHUNG, Na Ra OH, Yun Hee KIM, Jikhyon HAN, Hyun Ah MOON
-
Publication number: 20210388352Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.Type: ApplicationFiled: December 4, 2019Publication date: December 16, 2021Applicant: Tego Science Inc.Inventors: SaeWha JEON, Ho Yun CHUNG, Na Ra OH, Yun Hee KIM, Jik Hyon HAN, Hyun Ah MOON
-
Patent number: 11026876Abstract: The present invention relates to a composition for skin improvement containing at least one chemokine selected from the group consisting of B lymphocyte chemoattractant (BLC), also known as C-X-C motif ligand 13 (CXCL13), and thymus-expressed chemokine (TECK), also known as C-C motif ligand 25 (CCL25), as an active ingredient. Since the BLC (CXCL13) and TECK (CCL25) of the present invention increase the expression of proliferation marker Ki-67 and collagen IV, which are proteins concerning skin regeneration and skin elasticity, and exhibit excellent melanin-reducing and wound-healing effects and the ability to induce chemotaxis of keratinocytes, they can be applied in a cosmetic composition for skin improvement.Type: GrantFiled: July 28, 2017Date of Patent: June 8, 2021Assignee: Tego Science Inc.Inventors: Saewha Jeon, Yun Hee Kim, Jik Hyon Han, Hyun Ah Moon
-
Publication number: 20200188272Abstract: The present invention relates to a cosmetic composition having a cotton candy form. The cosmetic composition in a cotton candy form is prepared by freeze-drying an algin aqueous solution, and thus can be prepared through a simple process, has excellent moldability, and can stably contain, even at room temperature, a protein such as a cytokine, a peptide, and the like, which have particular storage requirements.Type: ApplicationFiled: November 22, 2017Publication date: June 18, 2020Applicant: TEGO SCIENCE INC.Inventors: Saewha JEON, Yun Hee KIM, Jikhyon HAN
-
Publication number: 20190175480Abstract: The present invention relates to a composition for skin improvement containing at least one chemokine selected from the group consisting of B lymphocyte chemoattractant (BLC), also known as C-X-C motif ligand 13 (CXCL13), and thymus-expressed chemokine (TECK), also known as C-C motif ligand 25 (CCL25), as an active ingredient. Since the BLC (CXCL13) and TECK (CCL25) of the present invention increase the expression of proliferation marker Ki-67 and collagen IV, which are proteins concerning skin regeneration and skin elasticity, and exhibit excellent melanin-reducing and wound-healing effects and the ability to induce chemotaxis of keratinocytes, they can be applied in a cosmetic composition for skin improvement.Type: ApplicationFiled: July 28, 2017Publication date: June 13, 2019Applicant: TEGO SCIENCE INC.Inventors: Saewha JEON, Yun Hee KIM, Jik Hyon HAN, Hyun Ah MOON
-
Patent number: 9220757Abstract: The present invention relates to an implantable composition for treating a damaged tissue and a method for inducing an in vivo migration of a cell for treatment to a damaged tissue region. The present invention treats the damaged tissue by inducing/promoting homing of a cell for tissue generation by implanting a biodegradable scaffold reacted with chemotactic factors (for example, IL-8 or MIP-3?) to a damaged location (for example, joint cartilage or skin). Thus, the composition of the present invention can not only be applied to the treatment of a damaged bone tissue, a joint cartilage, or a skin tissue more conveniently and efficiently compared to the conventional technology, but can also be used as a useful treatment supplement agent in cell treatment using allogeneic cell by enabling efficient utilization of cell resources for treatment, the cell resources which are high in scarcity.Type: GrantFiled: January 26, 2012Date of Patent: December 29, 2015Assignee: Tego Science Inc.Inventors: Jin Woo Lee, Min Sung Park, Yun Hee Kim
-
Publication number: 20140356948Abstract: There is provided a method for stably preserving cells and valuable materials included in the cells at room temperature by lyophilizing the cells. When the cells are lyophilized using a lyoprotectant, damage to the structure of the cells which may otherwise occur during a freezing process can be prevented, the lyophilized cells can be stored at room temperature, and the valuable material included in the cells may maintain the functions thereof at room temperature.Type: ApplicationFiled: December 10, 2012Publication date: December 4, 2014Applicant: TEGO SCIENCE INC.Inventors: Saewha Jeon, Ki Hoon Lee, Hankyu Jang
-
Publication number: 20140341865Abstract: There is provided a dressing for treating a wound. The dressing for healing a wound can be useful in maintaining a moisture environment at a wound site using a biocompatible polymer scaffold, and effectively promoting healing of a wound by various growth factors secreted by skin cells or stem cells attached to the biocompatible polymer scaffold as well.Type: ApplicationFiled: December 12, 2012Publication date: November 20, 2014Applicant: TEGO SCIENCE INC.Inventors: Saewha Jeon, Yun Hee Kim, Ho Yun Chung, Jin Hyun Choi, Hankyu Jang
-
Publication number: 20130344119Abstract: The present invention relates to an implantable composition for treating a damaged tissue and a method for inducing an in vivo migration of a cell for treatment to a damaged tissue region. The present invention treats the damaged tissue by inducing/promoting homing of a cell for tissue generation by implanting a biodegradable scaffold reacted with chemotactic factors (for example, IL-8 or MIP-3?) to a damaged location (for example, joint cartilage or skin). Thus, the composition of the present invention can not only be applied to the treatment of a damaged bone tissue, a joint cartilage, or a skin tissue more conveniently and efficiently compared to the conventional technology, but can also be used as a useful treatment supplement agent in cell treatment using allogeneic cell by enabling efficient utilization of cell resources for treatment, the cell resources which are high in scarcity.Type: ApplicationFiled: January 26, 2012Publication date: December 26, 2013Applicant: TEGO SCIENCE INCInventors: Jin Woo Lee, Min Sung Park, Yun Hee Kim